Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18363406 | 0.90 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363413 | 0.89 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363405 | 0.88 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363607 | 0.88 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363220 | 0.87 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363496 | 0.87 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363599 | 0.86 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363407 | 0.86 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 | |
| SCHEMBL18363409 | 0.86 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL18363487 | 0.85 | GRIN2B (1.00) | GRIN2BCYP2C9GRIN1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319963-B1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-01-08 | — | — | EP | claimed |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-13 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-9963447-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-08 | — | — | US | disclosed |
| US-9963447-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-08 | — | — | US | disclosed |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-12 | — | — | US | disclosed |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885CYP2C9 2384/4885GRIN1 6/4885 |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885CYP2C9 2384/4885GRIN1 6/4885 |
| US-20170008890-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885CYP2C9 2384/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.